Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- JHX +9.6% (guidance), STZ +3.5%, OR +2% (guidance)
Other news:
- TMQ +214.8% (confirms strategic investment by US government)
- LXEO +40.2% (announces progress in FDA discussions for accelerated approval pathway and positive interim clinical data for LX2006 in friedreich ataxia cardiomyopathy)
- JBIO +19.8% (enters $135 million private placement; unveils JADE201)
- DBVT +14% (sale of $30 mln worth of ADSs through ATM program)
- AMKR +10.6% (new semiconductor advanved packaging and test campus)
- DYN +9.8% (announces additional one-year clinical data demonstrating functional improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen)
- IREN +8.2% (secures new multi-year AI cloud contracts)
- MESO +4.7% (reports Q2 Ryoncil revs increased 66% post launch)
- GUTS +4.1% (reports potent preclinical results from RJVA-002, a dual GIP/GLP-1 gene therapy candidate for obesity)
- CLLS +3.1% (to present data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress)
- AMRC +2.5% (secures $197 mln energy infrastructure project)
- SMTC +2.3% (convertible notes offering)
- NEXM +2.3% (assay results from 4 additional holes of the 12 hole metallurgical drilling program)
- VINP +1.9% (acquires 50.1% stake in Verde Asset Management)
- CRWV +1.9% (to acquire Monolith)
- CIFR +1.4% (appoints new CFO)
- LOMA +1.4% (controlling shareholder approved a Judicial Reorganization; plan must be ratified by Court and approved by authorities)
- IONS +1.4% (showcases transformational medicines and industry-leading pipeline at Innovation Day)
- KALV +1.3% (new data of EKTERLY)
- ETHZ +1.2% (stock offering by selling shareholders, relates to convertible notes)
- GLOB +1.1% (new version of Globant Enterprise AI)
- RKLB +1% (sets launch schedule with Synspective)